AR106752A1 - Proteínas de unión a pd1 / ctla4 - Google Patents

Proteínas de unión a pd1 / ctla4

Info

Publication number
AR106752A1
AR106752A1 ARP160103541A ARP160103541A AR106752A1 AR 106752 A1 AR106752 A1 AR 106752A1 AR P160103541 A ARP160103541 A AR P160103541A AR P160103541 A ARP160103541 A AR P160103541A AR 106752 A1 AR106752 A1 AR 106752A1
Authority
AR
Argentina
Prior art keywords
immunoglobulin
variable domain
individual
ctla4
seq
Prior art date
Application number
ARP160103541A
Other languages
English (en)
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of AR106752A1 publication Critical patent/AR106752A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Adhesives Or Adhesive Processes (AREA)

Abstract

Reivindicación 1: Un dominio variable individual de inmunoglobulina (ISVD) multiespecífico que se une a PD1 humana y CTLA4 humana poniendo en contacto CTLA4 humana en uno o más de los siguientes residuos: VRVTVL (aminoácidos 33 - 38 de SEQ ID Nº 195), ADSQVTEVC (aminoácidos 41 - 49 de SEQ ID Nº 195) y CKVELMYPPPYYLG (aminoácidos 93 - 106 de SEQ ID Nº 195); o una proteína de unión de bloqueo cruzado que bloquea de forma cruzada la unión de dicho ISVD a PD1 y/o CTLA4. Reivindicación 17: Un polinucleótido que codifica el dominio variable individual de inmunoglobulina multiespecífico de una cualquiera de las reivindicaciones 1 - 15. Reivindicación 21: Un procedimiento para preparar un dominio variable individual de inmunoglobulina multiespecífico de una cualquiera de las reivindicaciones 1 - 15, que comprende introducir un polinucleótido que codifica el dominio variable individual de inmunoglobulina multiespecífico en una célula huésped y cultivar la célula huésped en un medio en condiciones favorables para la expresión de dicho dominio variable individual de inmunoglobulina multiespecífico a partir de dicho polinucleótido y, opcionalmente, purificar el dominio variable individual de inmunoglobulina multiespecífico a partir de dicha célula huésped y/o dicho medio. Reivindicación 26: Un procedimiento para tratar o evitar el cáncer o una enfermedad infecciosa en un sujeto que comprende administrar una cantidad eficaz de un dominio variable individual de inmunoglobulina multiespecífico de una cualquiera de las reivindicaciones 1 - 15 y 21 opcionalmente en asociación con un agente terapéutico adicional al sujeto.
ARP160103541A 2015-11-18 2016-11-18 Proteínas de unión a pd1 / ctla4 AR106752A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562256985P 2015-11-18 2015-11-18

Publications (1)

Publication Number Publication Date
AR106752A1 true AR106752A1 (es) 2018-02-14

Family

ID=57472065

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160103541A AR106752A1 (es) 2015-11-18 2016-11-18 Proteínas de unión a pd1 / ctla4

Country Status (15)

Country Link
US (1) US10544222B2 (es)
EP (1) EP3377526A1 (es)
JP (1) JP6779997B2 (es)
KR (1) KR20180083418A (es)
CN (1) CN109071639B (es)
AR (1) AR106752A1 (es)
AU (1) AU2016355568A1 (es)
BR (1) BR112018010085A2 (es)
CA (1) CA3003777A1 (es)
JO (1) JO3740B1 (es)
MA (1) MA43258A (es)
MX (1) MX2018006243A (es)
RU (1) RU2755724C2 (es)
TW (1) TWI782898B (es)
WO (1) WO2017087587A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
CN108653728B (zh) 2011-06-23 2022-11-18 埃博灵克斯股份有限公司 用于预测、检测和减少涉及免疫球蛋白单可变结构域的测定法中的非特异性蛋白干扰的技术
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
RS60717B1 (sr) 2014-05-16 2020-09-30 Ablynx Nv Varijabilni domeni imunoglobulina
MA42447A (fr) 2015-07-13 2018-05-23 Cytomx Therapeutics Inc Anticorps anti-pd-1, anticorps anti-pd-1 activables, et leurs procédés d'utilisation
BR112018008867A8 (pt) 2015-11-03 2019-02-26 Janssen Biotech Inc anticorpos que se ligam especificamente a pd-1 e seus usos
CA3005488A1 (en) * 2015-11-18 2017-05-26 Ablynx Nv Improved serum albumin binders
EA038179B1 (ru) 2015-11-18 2021-07-20 Мерк Шарп И Доум Корп. Ctla4-связывающие вещества
KR102194188B1 (ko) * 2015-11-18 2020-12-24 머크 샤프 앤드 돔 코포레이션 Pd1 및/또는 lag3 결합제
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
RU2764548C2 (ru) 2016-08-09 2022-01-18 Кимаб Лимитед Анти-icos антитела
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
WO2019122882A1 (en) 2017-12-19 2019-06-27 Kymab Limited Bispecific antibody for icos and pd-l1
AU2019205406A1 (en) * 2018-01-08 2020-08-27 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
CA3084518A1 (en) 2018-01-15 2019-07-18 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against pd-1
WO2020057611A1 (en) * 2018-09-20 2020-03-26 Wuxi Biologics (Shanghai) Co., Ltd. Novel bispecific ctla-4/pd-1 polypeptide complexes
CN113166262A (zh) * 2018-10-11 2021-07-23 英伊布里克斯公司 Pd-1单结构域抗体及其治疗组合物
WO2020181402A1 (zh) * 2019-03-10 2020-09-17 胡西木 一种抗肿瘤多肽及其应用
CN111892655B (zh) * 2019-05-06 2022-10-28 四川大学 抗pd-1纳米抗体的筛选及应用
WO2021110106A1 (en) * 2019-12-04 2021-06-10 Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Bispecific fusion protein for tumor treatment
AR120698A1 (es) 2019-12-09 2022-03-09 Ablynx Nv Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp
KR20220123237A (ko) 2019-12-09 2022-09-06 아블린쓰 엔.브이. Il-13 및 tslp를 표적으로 하는 면역글로불린 단일 가변 도메인을 포함하는 폴리펩타이드
WO2021170750A1 (en) * 2020-02-28 2021-09-02 Orega Biotech Combination therapies based on ctla4 and il-17b inhibitors
CN111944825A (zh) * 2020-08-24 2020-11-17 江苏集萃药康生物科技有限公司 一种ctla4基因和pd1基因人源化小鼠模型的应用
CN114573704B (zh) * 2021-03-10 2022-11-01 北京拓界生物医药科技有限公司 Pd-1/ctla-4结合蛋白及其医药用途
WO2023163968A1 (en) * 2022-02-24 2023-08-31 Merck Sharp & Dohme Llc Stable formulations of a multivalent vhh based cytotoxic t lymphocyte associated antigen 4 (ctla4) binder binding to human ctla4 and methods of use thereof
WO2024017281A1 (zh) * 2022-07-20 2024-01-25 明慧医药（杭州）有限公司 多特异性抗体及其用途

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1319120C (en) 1985-04-01 1993-06-15 John Henry Kenten Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
CA2145769A1 (en) 1992-09-29 1994-04-14 Gerald D. Fischbach Trophic factor having ion channel-inducing activity in neuronal cells
US6824779B1 (en) 1993-07-26 2004-11-30 Dana-Farber Cancer Institute, Inc. Methods for inhibiting the interaction of B7-2 with its natural ligand
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Hakko Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
US20020006403A1 (en) 1999-12-14 2002-01-17 Xue-Zhong Yu CD28-specific antibody compositions for use in methods of immunosuppression
US7795002B2 (en) 2000-06-28 2010-09-14 Glycofi, Inc. Production of galactosylated glycoproteins in lower eukaryotes
AU2001296962A1 (en) 2000-09-29 2002-04-08 Schering Corporation Pegylated interleukin-10
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
DK1345969T3 (da) 2000-12-26 2010-11-29 Inst Nat Sante Rech Med Anti-CD28-antistof
EP1456652A4 (en) 2001-11-13 2005-11-02 Dana Farber Cancer Inst Inc IMMUNOCELL ACTIVATION MODULATING SUBSTANCES AND USE METHOD THEREFOR
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
EP2258392A1 (en) 2002-11-08 2010-12-08 Ablynx N.V. Method of administering therapeutic polypeptides
ATE485307T1 (de) 2003-11-07 2010-11-15 Ablynx Nv Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung
WO2006040153A2 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
HUE045710T2 (hu) 2005-05-18 2020-01-28 Ablynx Nv Javított, alfa tumor nekrózis faktor elleni nanobodies
EP3243839A1 (en) * 2005-05-20 2017-11-15 Ablynx N.V. Improved nanobodies tm for the treatment of aggregation-mediated disorders
TWI323734B (en) * 2005-08-19 2010-04-21 Abbott Lab Dual variable domain immunoglobulin and uses thereof
CA2666599A1 (en) 2006-08-18 2008-02-21 Ablynx N.V. Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
WO2008071447A2 (en) * 2006-12-15 2008-06-19 Ablynx N.V. Amino acid sequences that modulate the interaction between cells of the immune system
KR101264473B1 (ko) 2007-05-24 2013-05-29 아블린쓰 엔.브이. Ｒａｎｋ-ｌ에 대한 아미노산 서열, 및 이를 포함하는 골 질환 및 장애 치료용 폴리펩티드
MX2010005783A (es) 2007-11-27 2010-08-10 Ablynx Nv Secuencias de aminoacidos dirigidas contra citoquinas heterodimericas y/o sus receptores y polipeptidos que comprenden las mismas.
US9212226B2 (en) 2008-05-16 2015-12-15 Ablynx N.V. Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same
EP2454285A2 (en) 2009-07-16 2012-05-23 Glaxo Group Limited Improved anti-serum albumin binding single variable domains
JP6023706B2 (ja) 2010-07-09 2016-11-09 アデュロ・バイオテック・ホールディングス・ヨーロッパ・ベスローテン・フエンノートシャップＡｄｕｒｏ Ｂｉｏｔｅｃｈ Ｈｏｌｄｉｎｇｓ， Ｅｕｒｏｐｅ Ｂ．Ｖ． Ｃｄ２７に対するアゴニスト抗体
CN108653728B (zh) 2011-06-23 2022-11-18 埃博灵克斯股份有限公司 用于预测、检测和减少涉及免疫球蛋白单可变结构域的测定法中的非特异性蛋白干扰的技术
ES2759936T3 (es) 2011-06-23 2020-05-12 Ablynx Nv Proteínas de unión a albúmina sérica
KR102162413B1 (ko) * 2011-08-17 2020-10-07 글락소 그룹 리미티드 변형된 단백질 및 펩티드
WO2013066765A1 (en) 2011-11-01 2013-05-10 Merck Sharp & Dohme Corp. Mutation of tup1 in glycoengineered yeast
JP2015531350A (ja) * 2012-09-13 2015-11-02 ノバルティス アーゲー 末端修飾を有する抗原結合分子
WO2014111550A1 (en) 2013-01-17 2014-07-24 Glaxosmithkline Intellectual Property Development Limited Modified anti-serum albumin binding proteins
ES2779123T3 (es) 2013-09-26 2020-08-13 Ablynx Nv Nanobodies biespecíficos
GB201322725D0 (en) * 2013-12-20 2014-02-05 Immodulon Therapeutics Ltd Cancer therapy
RS60717B1 (sr) 2014-05-16 2020-09-30 Ablynx Nv Varijabilni domeni imunoglobulina
CN104987421A (zh) * 2015-05-13 2015-10-21 北京比洋生物技术有限公司 抗ctla-4和pd-1的双重可变结构域免疫球蛋白

Also Published As

Publication number Publication date
TWI782898B (zh) 2022-11-11
KR20180083418A (ko) 2018-07-20
EP3377526A1 (en) 2018-09-26
CN109071639B (zh) 2022-07-08
WO2017087587A1 (en) 2017-05-26
JO3740B1 (ar) 2021-01-31
BR112018010085A2 (pt) 2018-11-13
RU2018121619A (ru) 2019-12-18
US20170137520A1 (en) 2017-05-18
JP2019502370A (ja) 2019-01-31
RU2755724C2 (ru) 2021-09-20
MX2018006243A (es) 2018-11-09
TW201726739A (zh) 2017-08-01
CA3003777A1 (en) 2017-05-26
CN109071639A (zh) 2018-12-21
MA43258A (fr) 2018-09-26
JP6779997B2 (ja) 2020-11-04
RU2018121619A3 (es) 2020-04-24
AU2016355568A1 (en) 2018-06-21
US10544222B2 (en) 2020-01-28

Similar Documents

Publication Publication Date Title
AR106752A1 (es) Proteínas de unión a pd1 / ctla4
AR106753A1 (es) Proteínas de unión a ctla4p
SA518400424B1 (ar) جزيئات الجسم المضاد لعلاج السرطان
EA201990293A1 (ru) Мультиспецифичные антитела против cd40 и cd137
CL2019001926A1 (es) Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017).
CO2018012415A2 (es) Proteínas de unión específica y usos de las mismas
EA201891366A1 (ru) Гуманизированные антитела против cd73
MX2020009366A (es) Anticuerpos anti-cd73 y usos de los mismos.
MY176332A (en) Multispecific antibody constructs
AR103868A1 (es) Anticuerpos anti-cd47 como agentes terapéuticos
AR102239A1 (es) Anticuerpos anti-ox40 humanizados y sus usos
AR104213A1 (es) Anticuerpos anti-cd38 como agentes terapéuticos
BR112017003582A2 (pt) anticorpos, composições e usos
MX2018004503A (es) Receptores de antigeno quimerico anti-cd30.
EA201590085A1 (ru) Антитела анти-egfr и их применение
EA201591131A1 (ru) Днк-конструкции антитела и способ их применения
AR101829A1 (es) Tratamiento de cáncer utilizando un receptor quimérico de antígeno cll-1
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
AR090047A1 (es) Dominio variable dual de inmunoglobulinas y sus usos
EA201792080A1 (ru) Гуманизированные анти-c1s антитела и способы их применения
MX358447B (es) Anticuerpos anti-psgl-1 y usos de los mismos.
EA201591791A1 (ru) Антитела pac1 человека
EA201991704A3 (ru) Моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
EA201690992A1 (ru) Антитела, специфичные к fcrn